Hospital
Central Tennessee Hospital Corporation
Central Tennessee Hospital Corporation was paid $30.16M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 99283, emergency room visit (moderate) — 50% of everything it billed.
33Billing provider infoCENTRAL TENNESSEE HOSPITAL CORPORATION
DICKSON, TN 37055
DICKSON, TN 37055
33aNPI1871530832assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.16M
24GClaims435,616
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#5 of 71
Median peer was paid$6.96M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,418 | $4.45M | |
| 2019 | 58,380 | $4.00M | |
| 2020 | 56,310 | $3.52M | |
| 2021 | 63,284 | $4.37M | |
| 2022 | 70,431 | $5.06M | |
| 2023 | 78,361 | $5.01M | |
| 2024incomplete | 45,432 | $3.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 50% | 61,628 | 56,017 | $15.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 44,060 | 37,581 | $10.67M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 30,835 | 26,029 | $1.38M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 8,552 | 8,149 | $1.28M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.1% | 1,201 | 996 | $334K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 3,655 | 1,502 | $330K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 1,000 | 713 | $302K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 595 | 433 | $192K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,197 | 3,793 | $113K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,211 | 4,389 | $104K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,486 | 1,398 | $67K |
| G0378 | Hospital observation service, per hour | <1% | 100 | 86 | $50K |
75 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,908 | $47K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 394 | $34K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,492 | $33K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 230 | $30K |
| 80053 | Comprehensive metabolic panel | <1% | 45,055 | $27K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,362 | $23K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 56 | $22K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $19K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 723 | $13K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 672 | $9K |
| 84484 | <1% | 13,238 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,241 | $2K |
| 85027 | <1% | 51,911 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,406 | $1K |
| 83605 | <1% | 790 | $1K | |
| 85730 | <1% | 3,359 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,414 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,360 | $867.43 |
| 11045 | <1% | 58 | $627.52 | |
| 82784 | <1% | 87 | $627.18 | |
| 71250 | <1% | 28 | $522.61 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,545 | $519.91 |
| 77336 | <1% | 45 | $468.13 | |
| 86258 | <1% | 73 | $468.06 | |
| 86364 | <1% | 73 | $468.06 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 962 | $389.98 |
| 81001 | <1% | 16,687 | $322.14 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,571 | $302.64 |
| 86231 | <1% | 72 | $245.25 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,852 | $216.94 |
| 84703 | <1% | 1,323 | $193.60 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,000 | $175.61 |
| 87070 | <1% | 1,516 | $155.31 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,996 | $149.41 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 743 | $108.00 |
| 83880 | <1% | 1,158 | $93.96 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,610 | $89.05 |
| 83690 | <1% | 8,712 | $82.29 | |
| 81003 | <1% | 6,494 | $66.33 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15 | $57.38 |
| 85651 | <1% | 30 | $34.79 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,970 | $27.37 |
| 81025 | <1% | 4,512 | $19.22 | |
| 86140 | <1% | 1,985 | $16.02 | |
| 85610 | <1% | 4,231 | $11.54 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 407 | $9.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,123 | $7.90 |
| 82550 | <1% | 1,475 | $5.86 | |
| 83735 | <1% | 2,129 | $4.22 | |
| 88312 | 0% | 108 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 331 | $0.00 |
| 87420 | 0% | 195 | $0.00 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 568 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 181 | $0.00 |
| 80076 | 0% | 83 | $0.00 | |
| 74018 | 0% | 190 | $0.00 | |
| 84100 | 0% | 64 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 15 | $0.00 |
| 73630 | 0% | 13 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 67 | $0.00 |
| 85379 | 0% | 58 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 106 | $0.00 |
| 82553 | 0% | 105 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 854 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 70 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 499 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 54 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 15 | $0.00 |
| 96376 | 0% | 17 | $0.00 | |
| 82150 | 0% | 48 | $0.00 | |
| 87040 | 0% | 230 | $0.00 | |
| 87077 | 0% | 36 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 53 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSLIGH, LAUREN (CFO)